Denali Therapeutics (DNLI) Revenue & Revenue Breakdown
Denali Therapeutics Revenue Highlights
Latest Revenue (Q)
$3.60M
Main Segment (Y)
Alzheimer's Disease Services
Main Geography (Y)
Alzheimer's Disease Services
Denali Therapeutics Revenue by Period
Denali Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | 100.00% |
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $330.53M | 204.74% |
| 2022-12-31 | $108.46M | 122.90% |
| 2021-12-31 | $48.66M | -85.50% |
| 2020-12-31 | $335.66M | 1158.19% |
| 2019-12-31 | $26.68M | -79.34% |
| 2018-12-31 | $129.16M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Denali Therapeutics generated - in revenue during NA 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Denali Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $3.60M | 100.00% |
| 2026-03-31 | - | 100.00% |
| 2025-12-31 | - | 100.00% |
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2023-09-30 | $1.27M | -99.57% |
| 2023-06-30 | $294.12M | 736.98% |
| 2023-03-31 | $35.14M | 241.74% |
| 2022-12-31 | $10.28M | 188.93% |
| 2022-09-30 | $3.56M | -93.22% |
| 2022-06-30 | $52.48M | 24.53% |
| 2022-03-31 | $42.14M | 236.75% |
| 2021-12-31 | $12.51M | 136.78% |
| 2021-09-30 | $5.29M | -76.96% |
| 2021-06-30 | $22.94M | 189.52% |
| 2021-03-31 | $7.92M | -97.50% |
| 2020-12-31 | $316.81M | 3272.88% |
| 2020-09-30 | $9.39M | 60.65% |
| 2020-06-30 | $5.85M | 62.24% |
| 2020-03-31 | $3.60M | -22.86% |
| 2019-12-31 | $4.67M | -65.66% |
| 2019-09-30 | $13.60M | 224.14% |
| 2019-06-30 | $4.20M | -0.19% |
| 2019-03-31 | $4.21M | -96.65% |
| 2018-12-31 | $125.68M | 10416.82% |
| 2018-09-30 | $1.20M | -27.49% |
| 2018-06-30 | $1.65M | 157.10% |
| 2018-03-31 | $641.00K | -99.56% |
| 2017-12-31 | $145.15M | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Denali Therapeutics generated $3.60M in revenue during Q2 2026, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Denali Therapeutics Revenue Breakdown
Denali Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.50M | $3.90M |
Denali Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 20: Alzheimer's Disease Services (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.40M | $3.40M | $3.40M | $3.40M | $3.60M | $3.70M | $3.80M |
Denali Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Alzheimer's Disease Services (100.00%).
Denali Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.50M | $3.90M |
Denali Therapeutics's latest annual revenue breakdown by geography, as of Dec 20: Alzheimer's Disease Services (100.00%).
Quarterly Revenue by Country
| Country | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|
| Alzheimer's Disease Services | $3.40M | $3.40M | $3.40M | $3.40M | $3.40M | $3.60M | $3.70M | $3.80M |
Denali Therapeutics's latest quarterly revenue breakdown by geography, as of Jun 21: Alzheimer's Disease Services (100.00%).
Denali Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $2.86B | $959.00M |
| IONS | Ionis Pharmaceuticals | $944.00M | $267.95M |
| ALEC | Alector | $21.05M | $3.32M |
| RAPP | Rapport Therapeutics | - | - |
| CGTX | Cognition Therapeutics | - | - |
| NMRA | Neumora Therapeutics | - | - |
| BHVN | Biohaven | - | - |
| PMN | ProMIS Neurosciences | - | - |
| DNLI | Denali Therapeutics | - | $3.60M |
| PRAX | Praxis Precision Medicines | - | - |
| AMLX | Amylyx Pharmaceuticals | - | - |